Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.

Songwen Lin,Jing Ji,Ying Liu,Hua Tian,Yan Zhang,Rong Fu,Jingbo Zhang,Mingjin Wang,Tingting Du,Ming Ji,Deyu Wu,Kehui Zhang,Li Sheng,Yan Li,Xiaoguang Chen,Heng Xu

DOI: https://doi.org/10.1021/acs.jmedchem.9b00969

IF: 8.039

2019-01-01

Journal of Medicinal Chemistry

Abstract:Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease, and its molecular pathogenesis remains poorly understood. Recently, emerging evidence demonstrates that the PI3K signaling transduction pathway is linked to the pathology of IPF. In this work, we rationally designed a new series of 4-methylquinazoline derivatives as highly potent PI3K inhibitors that significantly suppress the phosphorylation of the main PI3K downstream effectors and displays marked antiproliferative activity in mouse MLg2908 lung fibroblasts. In a bleomycin-induced mouse pulmonary fibrosis model, 5d from the series improved mouse lung function and slowed the progression of pulmonary fibrosis. Overall, this work promises a therapeutic potential for PI3K inhibitors to treat IPF.